FindTrial
Sign In

utidelone injection

DRUG7 trials

Sponsors

Beijing Biostar Pharmaceuticals Co., Ltd., Henan Cancer Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions

Advanced Breast CancerAdvanced Non-small Cell Lung CancerAdvanced or Metastatic CRCHER-2 Negative Breast CancerLocally Advanced or Metastatic Non-Small Cell Lung CancerMetastatic Urothelial CarcinomaSolid Tumor

Phase 2

Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
CompletedNCT03693547
Beijing Biostar Pharmaceuticals Co., Ltd.Advanced Non-small Cell Lung Cancer
Start: 2019-04-22End: 2021-08-10Updated: 2023-01-10
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer
SuspendedNCT03906565
Beijing Biostar Pharmaceuticals Co., Ltd.Advanced or Metastatic CRC
Start: 2019-04-12End: 2024-12-31Target: 30Updated: 2023-01-10
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
CompletedNCT04911907
Beijing Biostar Pharmaceuticals Co., Ltd.Solid Tumor
Start: 2021-01-22End: 2025-05-31Updated: 2026-04-03
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
RecruitingNCT05398861
Henan Cancer HospitalHER-2 Negative Breast Cancer
Start: 2022-08-19End: 2027-05-30Target: 79Updated: 2026-04-16
Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma
NCT05895864
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityMetastatic Urothelial Carcinoma
Start: 2023-06-07End: 2025-12-13Target: 34Updated: 2023-06-09

Phase 3

Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT05673590
Beijing Biostar Pharmaceuticals Co., Ltd.Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Start: 2023-05-12End: 2025-12-31Target: 612Updated: 2023-11-08
Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer
Not yet recruitingNCT07684456
Beijing Biostar Pharmaceuticals Co., Ltd.Advanced Breast Cancer
Start: 2026-08-01End: 2029-03-01Target: 308Updated: 2026-07-06

Related Papers

Efficacy and safety results of a multi-center phase II study of utidelone injection in combination with PD-1 inhibitor and chemotherapy for the first-line treatment of advanced gastric and esophagus cancers.
Journal of Clinical Oncology2025-05-28
A single-arm, multicenter, phase II study of utidelone in advanced solid tumors: Efficacy data from screening and the expansion cohort assessing utidelone plus sintilimab and oxaliplatin for advanced gastric cancer.
Journal of Clinical Oncology2024-06-01
Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801).
2023-10-292 citations